Adult acute lymphoblastic leukemia

Summary

Adult acute lymphoblastic leukemia (MONDO:0003541) is a cancer and 206 clinical trials. Top therapeutic interventions include cyclophosphamide anhydrous, mercaptopurine anhydrous, and doxorubicin. A subtype of acute lymphoblastic leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 206

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adult acute lymphoblastic leukemia
Mondo ID	MONDO:0003541
DOID	DOID:5604
NCIT	C4967
UMLS	C0751606
MedGen	199693
GARD	0023555
Is cancer (heuristic)	yes

Also known as: acute lymphoblastic leukaemia (ALL) · acute lymphoblastic leukemia (ALL) · adult acute lymphoblastic leukemia · adult acute lymphocytic leukaemia · adult acute lymphocytic leukemia · adult acute lymphogenous leukaemia · adult acute lymphogenous leukemia · adult acute lymphoid leukaemia · adult acute lymphoid leukemia · adult ALL · adult precursor lymphoblastic leukaemia · adult precursor lymphoblastic leukemia

Disease family

This is a subtype of acute lymphoblastic leukemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › precursor lymphoblastic lymphoma/leukemia › acute lymphoblastic leukemia › adult acute lymphoblastic leukemia

Related subtypes (11): childhood acute lymphoblastic leukemia, prolymphocytic leukemia, null-cell leukemia, B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, T-cell acute lymphoblastic leukemia, lymphoblastic leukemia, acute, with lymphomatous features, plasma cell leukemia, acute biphenotypic leukemia, precursor B-cell acute lymphoblastic leukemia, precursor T-cell acute lymphoblastic leukemia

Subtypes (2): B-cell adult acute lymphocytic leukemia, T-cell adult acute lymphocytic leukemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 206.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	63
PHASE2	51
Not specified	50
PHASE1/PHASE2	20
PHASE4	9
PHASE3	9
PHASE2/PHASE3	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00198978	PHASE4	COMPLETED	German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00198991	PHASE4	COMPLETED	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
NCT00199004	PHASE4	COMPLETED	Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
NCT00199056	PHASE4	COMPLETED	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
NCT00199069	PHASE4	COMPLETED	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
NCT00199095	PHASE4	COMPLETED	Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
NCT01735955	PHASE4	COMPLETED	Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
NCT02894645	PHASE4	UNKNOWN	Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
NCT05340985	PHASE4	UNKNOWN	Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis
NCT07297914	PHASE2/PHASE3	NOT_YET_RECRUITING	Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
NCT00199043	PHASE3	COMPLETED	Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
NCT00199108	PHASE2/PHASE3	COMPLETED	Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt
NCT00799461	PHASE3	COMPLETED	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
NCT00929695	PHASE3	COMPLETED	Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease
NCT01295710	PHASE3	COMPLETED	Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
NCT01305655	PHASE3	COMPLETED	Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
NCT01439347	PHASE3	TERMINATED	A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL
NCT01802814	PHASE3	COMPLETED	International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
NCT02072785	PHASE3	UNKNOWN	Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia
NCT02730299	PHASE3	COMPLETED	Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
NCT03564704	PHASE2/PHASE3	UNKNOWN	Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
NCT00792948	PHASE2	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
NCT02061800	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
NCT02094794	PHASE2	ACTIVE_NOT_RECRUITING	Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
NCT02727803	PHASE2	RECRUITING	Personalized NK Cell Therapy in CBT
NCT02790515	PHASE2	ACTIVE_NOT_RECRUITING	Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
NCT03590171	PHASE2	RECRUITING	International Study for Treatment of High Risk Childhood Relapsed ALL 2010
NCT03849651	PHASE2	ACTIVE_NOT_RECRUITING	TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
NCT05884333	PHASE2	RECRUITING	Cord Blood Transplant in Adults With Blood Cancers
NCT06220487	PHASE2	RECRUITING	A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
NCT07227584	PHASE2	NOT_YET_RECRUITING	ALL Backbone in AYAs
NCT00006251	PHASE1/PHASE2	COMPLETED	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
NCT00016016	PHASE1/PHASE2	COMPLETED	Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia
NCT00027820	PHASE1/PHASE2	COMPLETED	Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
NCT00031655	PHASE2	COMPLETED	Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission
NCT00036738	PHASE2	COMPLETED	Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
NCT00052520	PHASE1/PHASE2	COMPLETED	Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
NCT00068718	PHASE1/PHASE2	COMPLETED	Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
NCT00078858	PHASE1/PHASE2	COMPLETED	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
NCT00084916	PHASE2	COMPLETED	CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	21
MERCAPTOPURINE ANHYDROUS	4	19
DOXORUBICIN	4	18
DAUNORUBICIN	4	15
ASPARAGINASE	4	9
VINCRISTINE	4	8
CYTARABINE	4	7
BETAMETHASONE	4	6
DEXAMETHASONE	4	6
IDARUBICIN	4	6
METHOTREXATE	4	6
PREDNISOLONE	4	6
TENIPOSIDE	4	5
THIOGUANINE	4	5
2-MERCAPTOETHANESULFONIC ACID	4	4
BLINATUMOMAB	4	4
DASATINIB ANHYDROUS	4	4
BENDAMUSTINE HYDROCHLORIDE	4	3
ETOPOSIDE PHOSPHATE	4	3
FLUDARABINE PHOSPHATE	4	3
IFOSFAMIDE	4	3
NILOTINIB	4	3
VINDESINE	4	3
ALEMTUZUMAB	4	2
DEFERASIROX	4	2
IMATINIB	4	2
MITOXANTRONE	4	2
PEGASPARGASE	4	2
RASBURICASE	4	2
RITUXIMAB	4	2